2025 Volume 62 Issue 3 Pages 234-238
A 13-year-old girl was diagnosed with acute promyelocytic leukemia (APL) and treated with multi-agent chemotherapy, including all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). The patient was unsuccessfully treated with ATO induction therapy for relapsed APL 19 months later. However, the subsequent tamibarotene chemotherapy resulted in complete remission. During the second remission period, the patient underwent bone marrow transplantation from an HLA 8/8 allele-matched sibling with a myeloablative conditioning regimen comprising busulfan 11.2 mg/kg and melphalan 180 mg/m2. After engraftment on day 21, the patient experienced no acute graft-versus-host disease or other serious complications, and was discharged 96 days after transplantation.
Tamibarotene may be effective for patients with ATRA- and ATO-resistant relapsed APL, although reports in children are limited.
